Prestige Consumer Healthcare In (PBH) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

$1.13

Estimate

$1.07

Surprise

+5.3%

Revenue (period 2026-09-30)

$336.3M

Score today

5.3/10

Revenue source: xbrl.

Prestige Consumer Healthcare In (PBH) beat the $1.07 estimate with adjusted EPS of $1.13 — a clear 5.3% upside surprise.

• Prestige Consumer Lowers FY2027 Adj EPS Guidance from $4.55-$4.65 to $4.48-$4.55 vs $4.58 Est; Lowers FY2027 Sales Guida — benzinga, 2026-11-05

TrendMatrix currently rates PBH Sell at 5.3/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's +5.3% surprise compares with a +1.1% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$42.84

Price target

$58.99

Stop

$40.98

Upside to target

+37.7%

Reward-to-risk

3.5:1

Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Drug Manufacturers - Specialty & Generic

Market cap

$2.10B

P/E (fwd)

8.7

P/E (ttm)

13.7

52-week range

$42.62–$71.07

Off 52-week high

39.7%

RSI (14)

35

Volume vs avg

0.47×

Score today

5.3/10